GH21

DRUG3 trials

Sponsors

Suzhou Genhouse Bio Co., Ltd.

Conditions

Advanced Solid Tumor With Oncogenic Driver MutationsLocally Advanced or Metastatic Solid Tumors Harboring KRAS G12C MutationNon-Small Cell Lung Cancer With EGFR MutationPatients With Advanced Solid Tumor

Phase 1

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

RecruitingNCT06306456

Suzhou Genhouse Bio Co., Ltd.Non-Small Cell Lung Cancer With EGFR Mutation

Start: 2024-03-05End: 2026-12-31Target: 94Updated: 2024-07-08

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Not yet recruitingNCT06435455

Suzhou Genhouse Bio Co., Ltd.Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation

Start: 2024-07-01End: 2027-12-31Target: 126Updated: 2024-07-08

Phase 2

A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

RecruitingNCT06322095

Suzhou Genhouse Bio Co., Ltd.Advanced Solid Tumor With Oncogenic Driver Mutations, Patients With Advanced Solid Tumor

Start: 2024-03-22End: 2025-12-31Target: 72Updated: 2024-10-01